← Eichor
Condition: Acute Adult T Cell Leukemia Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Acute Adult T Cell Leukemia Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481241A Study of CTD402 in T-ALL/LBL Patients
Phase 1/Phase 2 · 8 location(s) · Imviva Bio · NCT07070219CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
Phase 1/Phase 2 · 1 location(s) · Bambino Gesù Hospital and Research Institute · NCT06064903Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Le
Phase 2 · 15 location(s) · Goethe University · NCT06648889Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Phase 1 · 16 location(s) · New York Medical College · NCT04972942uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109518CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
Phase 1 · 1 location(s) · National University Hospital, Singapore · NCT05043571Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
Phase N/A · 1 location(s) · Washington University School of Medicine · NCT07313592CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 · 5 location(s) · Tr1X, Inc. · NCT06462365BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Phase 1/Phase 2 · 2 location(s) · Chinese PLA General Hospital · NCT07008885CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2 · 1 location(s) · Northside Hospital, Inc. · NCT05909059Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Phase 1 · 1 location(s) · Stanford University · NCT06408194UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT05535855Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04033302Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT06934382A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
Phase 2 · 1 location(s) · St. Jude Children's Research Hospital · NCT06847269Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
Phase 1 · 1 location(s) · Bambino Gesù Hospital and Research Institute · NCT06080191Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05277753Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Phase 1/Phase 2 · 2 location(s) · Curocell Inc. · NCT04836507Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07312630Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06633354Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Co-administration of CART22-65s and huCART19 for B-ALL
Phase 1/Phase 2 · 1 location(s) · Stephan Grupp MD PhD · NCT05674175Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05376111
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.